(MedPage Today) — The FDA approved the kinase inhibitor gedatolisib (Revtorpyk) for treating hormone receptor (HR)-positive/HER2-negative breast cancer in patients whose disease has progressed on endocrine therapy in the metastatic setting. Approval…
Source: MedPage Today — Headlines
